Type
Blood Testing
Biomarkers
2
Duration
15 min
Sample
Blood (venous draw)
What's included
4 deliverables in this treatment
- Choice of tumour markers selected to age, sex and risk (PSA, free PSA, CEA, AFP, hCG, CA 125, CA 15-3, CA 19-9 and others)
- Venous blood draw at the institute
- Laboratory analysis by MOÚ's accredited oncology laboratory
- Results suitable for review with an oncologist
À-la-carte tumour-marker blood testing for self-payers at Masarykův onkologický ústav, selected to age, sex and personal risk rather than sold as a fixed bundle. Available markers include PSA and free PSA (prostate), CEA (broad-spectrum), AFP and hCG (germ-cell/liver), and CA 125, CA 15-3 and CA 19-9 (ovarian, breast and pancreatic/GI). Run by the institute's oncology laboratory, the markers are best interpreted alongside an oncologist consultation rather than read in isolation. Useful for monitoring known risk or complementing a preventive screen, with the same markers also embedded in the institute's full preventive checkup.
About this treatment
This service covers self-payer tumour-marker blood testing at Czechia's national comprehensive cancer centre. Rather than a fixed panel, MOÚ prices each marker individually so an oncologist can select the combination relevant to a person's age, sex, symptoms and family history — the approach recommended for tumour markers, which are most informative in context.
The available markers cover the main clinical uses: PSA and free PSA for prostate assessment in men; CEA as a broad-spectrum marker associated with colorectal and several other cancers; AFP and hCG for germ-cell and liver contexts; and CA 125, CA 15-3 and CA 19-9 for ovarian, breast and pancreatic/gastrointestinal contexts respectively. Additional markers such as NSE, SCC, CYFRA, HE4/ROMA, CA 72-4 and beta-2-microglobulin are also available from the…
Sampling is a standard venous blood draw, added once per visit; individual marker prices range from roughly 220 to 950 Kč. Results come from the institute's accredited oncology laboratory. Because a raised marker can occur in benign conditions and a normal marker does not exclude cancer, these tests are not a stand-alone screen — they are most valuable for monitoring a known risk, following a previously elevated value, or complementing a broader…
Good to know
- Selection
- Per-marker, not a fixed bundle
- Sample
- Single venous blood draw
- Best with
- Oncologist consultation for interpretation
Who is this for?
People monitoring a known risk or following a previously elevated marker, and self-payers complementing a preventive screen.
Preparation required
Generally no special preparation; follow any marker-specific instructions from the laboratory. Bring previous results so trends can be assessed.
Panel categories
Biomarkers tested
2A biomarker associated with some breast cancers; used to monitor treatment response in patients with metastatic breast cancer.
A biomarker commonly used in the diagnosis and management of pancreatic and gastrointestinal cancers. Elevated levels can also be found in other conditions such as liver disease.
About the clinic
Reviews, team and credentials
Independent review links and clinic-reported team information.
232 clinic reviews
From independent platforms
Clinical team
MOÚ is staffed by clinical oncologists, radiation and medical oncologists, radiologists, gynaecologists, gastroenterologists, pulmonologists and clinical geneticists across a multidisciplinary comprehensive cancer centre. Diagnostic and preventive self-payer services are delivered by the institute's specialist oncology and radiodiagnostic teams, with every preventive checkup concluding in a written assessment by a…
Languages: Czech, English
What clients say
"{"quote":"Ranked first of 35 Czech hospitals in the national patient-satisfaction assessment, with an average grade of 1.10 (≈97% satisfaction).","source":"Czech National Patient Satisfaction Assessment"}"
"{"quote":"4.5 out of 5 across 171 patient reviews on Firmy.cz.","source":"Firmy.cz"}"
Treatment highlights
- Choice of tumour markers selected to age, sex and risk (PSA, free PSA, CEA, AFP, hCG, CA 125, CA 15-3, CA 19-9 and others)
- Venous blood draw at the institute
+2 more items in What's included
Self-payer tumour markers are priced per test from MOÚ's individual price list — e.g. PSA 400 Kč, CEA 220 Kč, AFP 400 Kč, hCG 400 Kč, CA 125 500 Kč, CA 15-3 330 Kč, CA 19-9 330 Kč. The 400 Kč shown is the entry PSA test; a blood draw (150 Kč) is added once per visit. Final VAT-exempt price, payable by cash or card. Markers are selected to your age, sex and risk rather than run as a fixed bundle.